Jazz Pharmaceuticals plcJAZZNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +7.53% | -0.46% | +2.14% | +6.74% | +10.09% |
| Gross Profit Growth | +6.05% | -1.65% | +1.70% | -7.95% | +22.29% |
| EBITDA Growth | +0.82% | -48.29% | -241.85% | -44.56% | -29.83% |
| Operating Income Growth | +55.73% | -184.42% | -444.15% | -77.90% | +376.59% |
| Net Income Growth | +102.98% | +0.00% | -526.22% | +16.91% | +6.45% |
| EPS Growth | +110.67% | +0.00% | -538.06% | +18.29% | +3.80% |
| EPS Diluted Growth | +119.01% | +0.00% | -571.49% | +19.30% | +7.40% |
| Weighted Average Shares Growth | -3.26% | -2.49% | -2.68% | -1.17% | +0.74% |
| Weighted Average Shares Diluted Growth | -11.73% | -2.49% | -12.11% | -2.48% | -0.84% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +138.19% | +60.83% | -73.18% | +19.03% | -9.05% |
| Free Cash Flow Growth | +176.72% | +50.16% | -68.89% | +18.43% | -22.97% |
| Receivables Growth | +1.55% | -7.65% | +2.29% | +5.63% | +15.90% |
| Inventory Growth | -19.53% | -14.64% | -6.92% | -10.42% | -13.21% |
| Asset Growth | +5.43% | +1.83% | -3.68% | -7.34% | -2.94% |
| Book Value per Share Growth | +13.24% | +15.83% | +1.22% | -3.96% | +4.72% |
| Debt Growth | +6.40% | -6.31% | -6.19% | -12.47% | -12.22% |
| R&D Expense Growth | +11.03% | -18.93% | -13.94% | +20.40% | -28.73% |
| SG&A Expenses Growth | -6.75% | +46.15% | +5.87% | +62.89% | +10.00% |